Navigation Links
CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Date:9/11/2008

- Preliminary results to be presented on November 1, 2008 at 2008 iSBTc

Annual Meeting -

BRANFORD, Conn., Sept. 11 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, today announced that it has completed the enrollment of patients into its Phase II trial evaluating CR011-vcMMAE for the treatment of advanced melanoma. CuraGen also announced today that Phase II results from this trial will be presented during an oral session at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc), being held October 31 -- November 2, 2008, in San Diego, CA. The trial will be presented by Dr. Patrick Hwu, Co-Principal Investigator and Professor and Chairman of the Department of Melanoma Medical Oncology at The University of Texas, M.D. Anderson Cancer Center.

"We are very pleased with the clinical progress achieved with CR011-vcMMAE. Completing enrollment in this melanoma study ahead of schedule highlights the external support for this novel antibody-drug conjugate from our investigators," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen. "We expect that treatment of patients will still be ongoing in this Phase II trial at the time of iSBTc, and therefore look forward to presenting the first data from all treated patients in November, and anticipate that final results from the study will be available during the first half of 2009."

A total of 36 patients were enrolled in this Phase II open-label, multi-center trial evaluating the efficacy and safety of CR011-vcMMAE 1.88 mg/kg administered intravenously once every three weeks in patients with unresectable Stage III
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Israel, Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... developing octreotide capsules for the orphan condition acromegaly, ... ended June 30, 2015 and provided a corporate ... been a transformative time for Chiasma, as we ... announced that our first New Drug Application (NDA) ...
(Date:8/31/2015)... , August 31, 2015 ... that the global cardiovascular monitoring and diagnostic devices ... is predicted to reach a value of approximately ... of 9.7% between 2013 and 2019. The title ... Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular ...
(Date:8/31/2015)... NEW YORK , Aug. 31, 2015  Dipexium ... company focused on the development and commercialization of Locilex® ... peptide, today announced plans to participate in four investor ... September 2, 2015 at the Sidoti & Company, LLC ... City . David P. Luci , President ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... YORK, July 8, 2011 The U.S. Food and ... Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for ... for active booster immunization against tetanus, diphtheria and pertussis ... vaccine approved for use in this age group.  With ...
... July 8, 2011 /PRNewswire-Asia/ -- Shenzhen Wuzhou Changlian International ... of multifunctional medical and industrial products, is pleased to ... Up to a 35% discount will be offered in ... promotional activity range from infrared thermometers , digital ...
Cached Medicine Technology:GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 2GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 3GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 4Enjoy Only One Thermometer in Various Domains 2
(Date:9/1/2015)... Canada (PRWEB) , ... September ... ... announce PRO Archiver for Alfresco, a next-generation customer communications archiving solution ... built with market-leading technology from Crawford and helps organizations save millions of ...
(Date:9/1/2015)... ... September 01, 2015 , ... Award-winning ... pick-up artists about their experiences of female beauty, women’s emotions, fertility, female violence ... issues, as well as their relationships with other men, documenting how the power ...
(Date:9/1/2015)... ... 01, 2015 , ... Anthony J. Tantillo, Esq., Attorney from William Mattar ... consecutive year in a row. Through nomination, research and strategic evaluation processes, Tantillo ... Niagara Falls, New York, Tantillo is a Buffalo State College graduate of 1998. ...
(Date:9/1/2015)... ... ... A new episode of “Voices In America”, hosted by famous actor and voice over ... are over 100 different types of arthritis. One of the most popular is rheumatoid ... shed light on this important topic. , Anyone who is nearing their golden years ...
(Date:9/1/2015)... CO. (PRWEB) , ... September 01, 2015 , ... September ... and product manufacturers use safety labels and stickers to keep little ones' safety top ... year Baby Safety Month has a particular focus. According to the JPMA's Baby Safety ...
Breaking Medicine News(10 mins):Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3
... phone users were closely monitored by scientists in Denmark from ... of cell phone usage. Almost half a million, were regular ... using cell phones for almost 2 decades. ... the electromagnetic waves emitted by cell phones, are capable of ...
... to insufficient doctors, midwives or due to lack of wards. ... off their// meetings, according to a recent study. ... according to which during 10% of the emergencies during childbirth, ... guidelines. ,Not many consultants were going for ward ...
... to exploit the passion for cricket among South Asians to ... to delay calling// emergency help when experiencing chest pain. ... 40-50 per cent higher death rate from heart disease than ... reluctant to seek emergency help for various reasons: doubt, embarrassment, ...
... to Lindsay Reaves of the University of Minnesota School of ... basis tend to have a healthier// lifestyle and diet. ... Dietetic Association were based on a survey of more than ... weight, behaviors and diet. ,The aim of ...
... has suggested that Marijuana is not a “gateway” drug that ... call into question the long-held belief that has shaped prevention ... a parent to panic upon discovering a bag of pot ... tracked 214 boys beginning at ages 10-12, all of whom ...
... epilepsy drug, lacosamide, developed by U.S firm Schwarz has found ... patients// not controlled by other drugs - the company said ... ,The results of the 485-patient study were presented ... that epileptics treated with a 200-mg dose of the drug, ...
Cached Medicine News:Health News:British Heart Experts Use Cricket To Target South Asians 2Health News:Teen Marijuana Use Does Not Predict Drug, Alcohol Abuse 2Health News:Teen Marijuana Use Does Not Predict Drug, Alcohol Abuse 3
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Achievement, available exclusively from Art Optical, is a unique RGP lens design with a patented junctionless back surface and a controlled edge lift....
... Lifestyle Gp is a ... multi-aspheric back surface. Through a ... surface curves, the LifeStyle Gp ... of add. Plus, its multi-aspheric ...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
Medicine Products: